Purpose Quizartinib pharmacokinetics in FLT3-ITD negative acute myeloid leukemia (AML) remain largely unexplored. This study aims to validate a population pharmacokinetics model (popPK) for quizartinib in plasma samples of FLT3-ITD negative AML patients. To do so, an ultra-performance liquid chromatography coupled with tandem mass spectrometry (UPLC-MS/MS) method has been developed and validated for the quantification of quiza...

Cognitive decline is a major non-motor symptom in Parkinson’s disease (PD), often linked to brain atrophy. This study examines the relationship between cortical atrophy and age groups in predicting cognitive decline in PD over five years. 188 PD patients from the COPPADIS cohort were stratified by age: young (30–55 years, N = 47), middle-aged (56–65 years, N = 59), and older adults (66–75 years, N = 82). Baseline cortical volu...